Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

@article{Andr2014EverolimusFW,
  title={Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.},
  author={Fabrice Andr{\'e} and Ruth M O'regan and Mustafa Ozguroglu and Masakazu Toi and Binghe Xu and Guy H M Jerusalem and Norikazu Masuda and Sharon T Wilks and Francis P. Arena and Claudine Isaacs and Yoon-Sim Yap and Zsuzsanna P{\'a}pai and Istv{\'a}n L{\'a}ng and Anne C. Armstrong and Guillermo Luis Lerzo and Michelle White and Kun-wei Shen and Jennifer K Litton and David DY Chen and Yufen Zhang and Shyanne Ali and Tetiana Taran and Luca Gianni},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 6},
  pages={580-91}
}
BACKGROUND Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab. METHODS In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS
133 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 133 extracted citations

Similar Papers

Loading similar papers…